Genmab — Marts 2024
-
A bispecific antibody to treat bleeding disorders https://www.nature.com/natcardiovascres/volumes/3/issues/2 // A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders https://www.nature.com/articles/s44161-023-00418-4
-
Hemab Therapeutics
@Hemab_Tx
Preclinical data on HMB-001 in the February 2024 issue of
@NatureCVR
: Let’s take a deep dive to learn what the results show and what it may signal for the future of treatment for bleeding disorders like #GlanzmannThrombasthenia (GT). https://twitter.com/Hemab_Tx/status/1767574739155898493 -
Det er ikke oplyst: At the Annual General Meeting on March 13, 2024, the Board of Directors will propose the Annual General Meeting authorizes the Board of Directors to allow the Company to initiate a new share buyback program of up to DKK 3.5 billion.
-
De køber efter Safe Harbour reglerne - begrænsning i dagligt køb i.f.t. totale omsætning på dagen.
-
Derfor vil der også, som ved det seneste tilbagekøb, alene blive angivet en forventet slutdato
-
bliver først oplyst samtidig med annoncering af tilbagekøbets igangsætning.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind